NASDAQ: SILO - Silo Pharma, Inc.

六个月盈利: -50.49%
部门: Healthcare

促销时间表 Silo Pharma, Inc.

先进的时间表 简单图表
Financial Markets by TradingView

关于公司

Silo Pharma. Inc., a developmental stage biopharmaceutical company, focuses on merging traditional therapeutics with psychedelic research. The company's developing solutions to address various underserved conditions. It also seeks to acquire and/or develop intellectual property or technology rights from universities and researchers to treat rare diseases, including the use of psychedelic drugs, such as psilocybin, and the benefits they may have in certain cases involving depression, mental health issues, and neurological disorders.

更多详情
The company focuses on merging traditional therapeutics with psychedelic research for people suffering from indications, such as depression, post-traumatic stress disorder, Alzheimer's, Parkinson's, and other rare neurological disorders. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is headquartered in Englewood Cliffs, New Jersey.
添加到比较列表
添加到观察列表
添加到投资组合
添加价格通知

Цена ао 1.94
Выручка 4.1E-5
EBITDA -0.000902
Число акций ао 0.00308 млрд
P/E 3.5
P/S 219.82
P/BV -389.57
EV/EBITDA -9.83
Сайт https://silopharma.com
Валюта usd
IPO date 2014-05-13
Sector Health Care
Industry Biotechnology
Валюта отчета usd
每日价格变化: -3.77% (1.06)
每周价格变化: -3.77% (1.06)
每月价格变化: -9.73% (1.13)
3个月内价格变化: +5.92% (0.963)
六个月内的价格变化: -50.49% (2.06)
每年价格变化: -36.25% (1.6)
3年内价格变化: +466.67% (0.18)
5年内价格变化: +12 339.02% (0.0082)
年初以来价格变化: -35.85% (1.59)
所有参数

低估

姓名 意义 年级
P/S 68.34 1
P/BV 0.7978 9
P/E 0 0
EV/EBITDA -0.364 0
全部的: 4.63

效率

姓名 意义 年级
ROA, % -47.77 0
ROE, % -59.91 0
全部的: 0

股息

姓名 意义 年级
Div yield, % 0 0
DSI 0 0
全部的: 0

责任

姓名 意义 年级
Debt/EBITDA 0 10
全部的: 9.8

成长冲动

姓名 意义 年级
盈利能力 Revenue, % 75.86 8
盈利能力 Ebitda, % 327.45 10
盈利能力 EPS, % -46.12 0
全部的: 7.6
更多详情

机构 体积 分享, %
Financial Advocates Investment Management 62807 0.06
UBS Group AG 32843 0.03
Vanguard Group Inc 16334 0.02
Geode Capital Management, LLC 16179 0.02
TWO SIGMA SECURITIES, LLC 12788 0.01
State Street Corporation 12500 0.01
Tower Research Capital LLC (TRC) 7007 0.01
Westside Investment Management, Inc. 94 0
FWL INVESTMENT MANAGEMENT, LLC 80 0
Wells Fargo & Company 20 0

ETF 分享, % 本年盈利能力, % 股息, %
Avantis Emerging Markets Equity ETF 0.00003 11.542669584245 3.60513
Dimensional Emerging Markets Core Equity 2 ETF 0.00246 15.961857379768 3.34087
Dimensional Emerging Markets Value ETF 0.00004 17.066115702479 4.19508
SPDR S&P Emerging Markets Small Cap ETF 0.01392 9.4592150479291 3.03583
FlexShares Morningstar Emerging Markets Factor Tilt Index Fund 0.00179 12.462475271255 3.59676



导师 职称 支付 出生年份
Mr. Eric Weisblum Chairman, President & CEO 569.01k 1970 (54 年)
Mr. Daniel E. Ryweck Chief Financial Officer 62.69k 1965 (59 年)
Dr. James S. Kuo M.B.A., M.D. Vice President of Research & Development N/A 1965 (59 年)

地址: United States, Englewood Cliffs. NJ, 560 Sylvan Avenue - 在 Google 地图中打开, 打开 Yandex 地图
网站: https://silopharma.com